Anti-angiogenic Effect of Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(ZD1839) against Murine Renal Cell Carcinoma Orthotopic Model.
- Author:
Hea Young OH
1
;
Soo Mee KWON
;
Sun Il KIM
;
Sung Joon HONG
Author Information
1. Department of Urology, Urological Science Institute and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Renal cell carcinoma;
Pathologic neovascularization;
ZD1839, Genistein
- MeSH:
Angiogenesis Inhibitors;
Animals;
Carcinoma, Renal Cell*;
Epidermal Growth Factor*;
Gelatin Sponge, Absorbable;
Genistein;
Inhibitory Concentration 50;
Kidney;
Mice;
Microvessels;
Neovascularization, Pathologic;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor*;
Sepharose;
Tumor Burden;
Vascular Endothelial Growth Factor A;
von Willebrand Factor
- From:Korean Journal of Urology
2004;45(3):255-262
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: ZD1839(IressaTM) is a selective epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) known to block the cell signaling pathway. However, the effect of ZD1839 in relation to renal cell carcinoma, which is highly angiogenic, has not been reported. Using an orthotopic model of murine renal cell carcinoma(Renca), we evaluated the inhibitory effect of ZD1839 on tumor growth and angiogenesis. MATERIALS AND METHODS: Renca cells (1x10(4)cells/10microliter) were first adsorbed in Gelfoam and were implanted into the balb/cj mouse kidney followed by obturation with the agarose bar. Then, tumor formation was assessed every week for 4 weeks. IC50 was obtained for ZD1839 and genistein in vitro. 7 days after the implantation, the mice were divided into three groups, and normal saline, ZD1839(40mg/kg/day), and genistein (80mg/kg/day) were subcutaneously injected for 14 days. 21 days after the implantation, the mice were sacrificed, and tumor volume measurement and analysis of microvessel density(MVD) were performed using the factor VIII-related antigen and vascular endothelial growth factor(VEGF). RESULTS: Renca tumors, which formed in the renal parenchyme and had a circular shape, reached the peak growth velocity between 14 and 21 days. MVD was the highest at 14 days of implantation. IC50 for ZD1839 and genistein were 4.68microM and 5.43microM, respectively. Tumor growth after the treatment with ZD1839 and genstein was inhibited by 86%(p<0.01) and 49%(p<0.05), respectively, compared to the control. MVD of ZD1839 and genistein-treated groups were 50%(p<0.01) and 29%(p<0.05) lower, respectively, and VEGF levels were 24%(p<0.05) and 27%(p<0.05) lower, respectively, compared to the control. CONCLUSIONS: This orthotopic implantation method of the Renca cell is an effective model for demonstrating the effect of an angiogenesis inhibitor. Our results suggest that the anti-angiogenesis effect of ZD1839 in the Renca orthotopic implantation model partially contributes to the tumor growth inhibition, and that ZD1839 may be more effective than genistein in the tumor growth regulation through the inhibition of angiogenesis.
